AstraZeneca PLC 2025 AR2
The report presents the consolidated financial statements of AstraZeneca for the fiscal year ended December 31, 2025. The company reported total revenue of $58,739 million, up from $54,073 million in 2024, driven by product sales of $55,573 million. Operating profit increased to $13,743 million, and profit after tax reached $10,233 million. The report also outlines the company's accounting policies, financial risk management, and notes on legal proceedings and commitments.
Company: AstraZeneca PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2025
Type: AR2
Pages: 232
Back to company
AstraZeneca PLC
Annual Report And Form 20-F Information
The report presents the consolidated financial statements of AstraZeneca for the fiscal year ended December 31, 2025. The company reported total revenue of $58,739 million, up from $54,073 million in 2024, driven by product sales of $55,573 million. Operating profit increased to $13,743 million, and profit after tax reached $10,233 million. The report also outlines the company's accounting policies, financial risk management, and notes on legal proceedings and commitments.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees